Geode Capital Management LLC boosted its position in shares of argenx SE (NASDAQ:ARGX - Free Report) by 1.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 27,207 shares of the company's stock after acquiring an additional 458 shares during the period. Geode Capital Management LLC's holdings in argenx were worth $16,732,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. Sanctuary Advisors LLC raised its stake in argenx by 17.5% during the 3rd quarter. Sanctuary Advisors LLC now owns 2,064 shares of the company's stock valued at $1,119,000 after acquiring an additional 308 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of argenx during the third quarter worth about $652,000. Lord Abbett & CO. LLC purchased a new position in shares of argenx during the 3rd quarter worth approximately $88,339,000. GAMMA Investing LLC boosted its stake in shares of argenx by 44.8% in the fourth quarter. GAMMA Investing LLC now owns 252 shares of the company's stock valued at $155,000 after buying an additional 78 shares in the last quarter. Finally, Central Pacific Bank Trust Division acquired a new stake in argenx in the fourth quarter valued at $615,000. Hedge funds and other institutional investors own 60.32% of the company's stock.
Analysts Set New Price Targets
ARGX has been the subject of a number of research reports. Truist Financial reaffirmed a "buy" rating and set a $700.00 price objective (up from $660.00) on shares of argenx in a report on Tuesday, January 14th. William Blair restated an "outperform" rating on shares of argenx in a report on Friday, February 28th. JMP Securities raised their target price on shares of argenx from $606.00 to $696.00 and gave the stock a "market outperform" rating in a research report on Tuesday, January 14th. Guggenheim lifted their price objective on argenx from $775.00 to $1,100.00 and gave the company a "buy" rating in a research report on Monday, March 10th. Finally, Wedbush restated an "outperform" rating and issued a $715.00 price target on shares of argenx in a report on Friday, April 11th. Three equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, argenx has an average rating of "Moderate Buy" and an average price target of $699.28.
View Our Latest Research Report on argenx
argenx Price Performance
argenx stock traded up $4.68 during midday trading on Thursday, hitting $599.33. 190,297 shares of the stock were exchanged, compared to its average volume of 307,936. The company has a 50 day moving average price of $599.54 and a two-hundred day moving average price of $606.69. The firm has a market cap of $36.60 billion, a P/E ratio of -681.54 and a beta of 0.60. argenx SE has a 1 year low of $352.77 and a 1 year high of $678.21.
argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $761.22 million for the quarter, compared to analysts' expectations of $678.52 million. As a group, analysts predict that argenx SE will post 3.13 EPS for the current year.
argenx Company Profile
(
Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Read More
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
